Select therapeutic use:

Bladder, kidney, and other urologic cancers:

Indications for Vincristine Sulfate PFS:

In combination with other chemotherapeutic agents for Wilms' tumor.

Adult:

Usual dose: 1.4mg/m2 IV once weekly. Serum bilirubin >3mg/100mL: reduce dose by 50%.

Children:

≤10kg: initially 0.05mg/kg IV once weekly. >10kg: usual dose: 2mg/m2 IV once weekly.

Contraindications:

Demyelinating form of Charcot-Marie-Tooth syndrome.

Boxed Warning:

Should be administered by experienced individuals. For IV use only; fatal if given by other routes (eg, intrathecal).

Warnings/Precautions:

Pre-existing neuromuscular disease. Obtain CBCs, platelets before each dose, then periodically. Monitor serum uric acid levels during first 3–4 weeks of treatment. Avoid extravasation. Hepatic dysfunction. Pregnancy (Cat.D); avoid use. Nursing mothers: not recommended.

Pharmacologic Class:

Antimicrotubule agent.

Interactions:

Concomitant radiotherapy through ports that include the liver: not recommended. Potentiated by CYP3A4 enzyme inhibitors (eg, itraconazole). Antagonizes phenytoin. Caution with other neurotoxic or platinum-containing agents. Separate L-asparaginase dose by 12–24hrs (administer after vincristine). Consider discontinuing drugs that cause urinary retention for the first few days following therapy.

Adverse Reactions:

GI upset, paralytic ileus (esp. in children; discontinue temporarily if occurs), polyuria, dysuria, urinary retention, hypertension, hypotension, neuromuscular effects, dyspnea, bronchospasm, alopecia, rash, fever, headache, hypersensitivity reactions, acute uric acid nephropathy.

Note:

Formerly known under the brand name Vincasar PFS.

How Supplied:

Contact supplier

Bone and connective tissue cancer:

Indications for Vincristine Sulfate PFS:

In combination with other chemotherapeutic agents for rhabdomyosarcoma.

Adult:

Usual dose: 1.4mg/m2 IV once weekly. Serum bilirubin >3mg/100mL: reduce dose by 50%.

Children:

≤10kg: initially 0.05mg/kg IV once weekly. >10kg: usual dose: 2mg/m2 IV once weekly.

Contraindications:

Demyelinating form of Charcot-Marie-Tooth syndrome.

Boxed Warning:

Should be administered by experienced individuals. For IV use only; fatal if given by other routes (eg, intrathecal).

Warnings/Precautions:

Pre-existing neuromuscular disease. Obtain CBCs, platelets before each dose, then periodically. Monitor serum uric acid levels during first 3–4 weeks of treatment. Avoid extravasation. Hepatic dysfunction. Pregnancy (Cat.D); avoid use. Nursing mothers: not recommended.

Pharmacologic Class:

Antimicrotubule agent.

Interactions:

Concomitant radiotherapy through ports that include the liver: not recommended. Potentiated by CYP3A4 enzyme inhibitors (eg, itraconazole). Antagonizes phenytoin. Caution with other neurotoxic or platinum-containing agents. Separate L-asparaginase dose by 12–24hrs (administer after vincristine). Consider discontinuing drugs that cause urinary retention for the first few days following therapy.

Adverse Reactions:

GI upset, paralytic ileus (esp. in children; discontinue temporarily if occurs), polyuria, dysuria, urinary retention, hypertension, hypotension, neuromuscular effects, dyspnea, bronchospasm, alopecia, rash, fever, headache, hypersensitivity reactions, acute uric acid nephropathy.

Note:

Formerly known under the brand name Vincasar PFS.

How Supplied:

Contact supplier

CNS cancers:

Indications for Vincristine Sulfate PFS:

In combination with other chemotherapeutic agents for neuroblastoma.

Adult:

Usual dose: 1.4mg/m2 IV once weekly. Serum bilirubin >3mg/100mL: reduce dose by 50%.

Children:

≤10kg: initially 0.05mg/kg IV once weekly. >10kg: usual dose: 2mg/m2 IV once weekly.

Contraindications:

Demyelinating form of Charcot-Marie-Tooth syndrome.

Boxed Warning:

Should be administered by experienced individuals. For IV use only; fatal if given by other routes (eg, intrathecal).

Warnings/Precautions:

Pre-existing neuromuscular disease. Obtain CBCs, platelets before each dose, then periodically. Monitor serum uric acid levels during first 3–4 weeks of treatment. Avoid extravasation. Hepatic dysfunction. Pregnancy (Cat.D); avoid use. Nursing mothers: not recommended.

Pharmacologic Class:

Antimicrotubule agent.

Interactions:

Concomitant radiotherapy through ports that include the liver: not recommended. Potentiated by CYP3A4 enzyme inhibitors (eg, itraconazole). Antagonizes phenytoin. Caution with other neurotoxic or platinum-containing agents. Separate L-asparaginase dose by 12–24hrs (administer after vincristine). Consider discontinuing drugs that cause urinary retention for the first few days following therapy.

Adverse Reactions:

GI upset, paralytic ileus (esp. in children; discontinue temporarily if occurs), polyuria, dysuria, urinary retention, hypertension, hypotension, neuromuscular effects, dyspnea, bronchospasm, alopecia, rash, fever, headache, hypersensitivity reactions, acute uric acid nephropathy.

Note:

Formerly known under the brand name Vincasar PFS.

How Supplied:

Contact supplier

Leukemias, lymphomas, and other hematologic cancers:

Indications for Vincristine Sulfate PFS:

Acute leukemia. In combination with other chemotherapeutic agents for Hodgkin's disease, non-Hodgkin's malignant lymphomas (lymphocytic, mixed-cell, histiocytic, undifferentiated, nodular, diffuse types).

Adult:

Usual dose: 1.4mg/m2 IV once weekly. Serum bilirubin >3mg/100mL: reduce dose by 50%.

Children:

≤10kg: initially 0.05mg/kg IV once weekly. >10kg: usual dose: 2mg/m2 IV once weekly.

Contraindications:

Demyelinating form of Charcot-Marie-Tooth syndrome.

Boxed Warning:

Should be administered by experienced individuals. For IV use only; fatal if given by other routes (eg, intrathecal).

Warnings/Precautions:

Pre-existing neuromuscular disease. Obtain CBCs, platelets before each dose, then periodically. Monitor serum uric acid levels during first 3–4 weeks of treatment. Avoid extravasation. Hepatic dysfunction. Pregnancy (Cat.D); avoid use. Nursing mothers: not recommended.

Pharmacologic Class:

Antimicrotubule agent.

Interactions:

Concomitant radiotherapy through ports that include the liver: not recommended. Potentiated by CYP3A4 enzyme inhibitors (eg, itraconazole). Antagonizes phenytoin. Caution with other neurotoxic or platinum-containing agents. Separate L-asparaginase dose by 12–24hrs (administer after vincristine). Consider discontinuing drugs that cause urinary retention for the first few days following therapy.

Adverse Reactions:

GI upset, paralytic ileus (esp. in children; discontinue temporarily if occurs), polyuria, dysuria, urinary retention, hypertension, hypotension, neuromuscular effects, dyspnea, bronchospasm, alopecia, rash, fever, headache, hypersensitivity reactions, acute uric acid nephropathy.

Note:

Formerly known under the brand name Vincasar PFS.

How Supplied:

Contact supplier